A New Age-related Cutoff of Medial Temporal Atrophy Scale on MRI Improving the Diagnostic Accuracy of Neurodegeneration Due to Alzheimer's Disease in a Chinese Population
Overview
Authors
Affiliations
Background: Visual rating scales are still the most popular tools in assessing atrophy degrees of whole brain and lobes. However, the false negative rate of the previous cutoff score of visual rating scales was relatively high for detecting dementia of Alzheimer's type (DAT). This study aimed to evaluate the diagnostic value of new cutoffs of visual rating scales on magnetic resonance imaging for discriminating DAT in a Chinese population.
Methods: Out of 585 enrolled subjects, 296 participants were included and diagnosed as normal cognition (NC)(n = 87), 138 diagnosed as amnestic mild cognitive impairment (aMCI), and 71 as dementia of Alzheimer's type (DAT). Receiver operating characteristic (ROC) curve analyses were used to calculate the diagnostic value of visual rating sales (including medial temporal atrophy (MTA), posterior atrophy rating scale (PA),global cortical atrophy scale (GCA) and medial temporal-lobe atrophy index (MTAi))for detecting NC from DAT .
Results: Scores of MTA correlated to age and Mini-mental state examination score. When used to detect DAT from NC, the MTA showed highest diagnostic value than other scales, and when the cutoff score of 1.5 of MTA scale, it obtained an optimal sensitivity (84.5%) and specificity (79.1%) respectively, with a 15.5% of false negative rate. Cutoff scores and diagnostic values were calculated stratified by age. For the age ranges 50-64, 65-74, 75-84 years, the following cut-offs of MTA should be used, ≥1.0(sensitivity and specificity were 92.3 and 68.4%), ≥1.5(sensitivity and specificity were 90.4 and 85.2%), ≥ 2.0(sensitivity and specificity were 70.8 and 82.3%) respectively. All of the scales showed relatively lower diagnostic values for discriminating aMCI from NC.
Conclusions: The new age-based MTA cutoff showed better diagnostic accuracy for detecting DAT than previous standard, the list of practical cut-offs proposed here might be useful in clinical practice.
"Advances in biomarker discovery and diagnostics for alzheimer's disease".
Bhatia V, Chandel A, Minhas Y, Kushawaha S Neurol Sci. 2025; .
PMID: 39893357 DOI: 10.1007/s10072-025-08023-y.
Choe Y, Kim R, Kim H, Kim J, Lee H, Lee M J Alzheimers Dis Rep. 2024; 8(1):863-876.
PMID: 38910943 PMC: 11191633. DOI: 10.3233/ADR-230105.
The impact of medial temporal and parietal atrophy on cognitive function in dementia.
Susianti N, Prodjohardjono A, Vidyanti A, Setyaningsih I, Gofir A, Setyaningrum C Sci Rep. 2024; 14(1):5281.
PMID: 38438548 PMC: 10912680. DOI: 10.1038/s41598-024-56023-3.
Essien M, Lah J, Weinberg B, Allen J, Hu R AJNR Am J Neuroradiol. 2023; 44(12):1411-1417.
PMID: 38050003 PMC: 10714860. DOI: 10.3174/ajnr.A8049.
Mai Y, Cao Z, Zhao L, Yu Q, Xu J, Liu W CNS Neurosci Ther. 2023; 30(4):e14492.
PMID: 37864441 PMC: 11017425. DOI: 10.1111/cns.14492.